News | OGI News

PBDF funded company InDanio CEO interviewed by BioTuesdays

In an interview with BioTuesdays, InDanio Bioscience’s CEO Prakash Gowd explains the company’s nuclear receptor drug screening platform, and how it plans to leverage the technology commercially and build value. In 2010, InDanio received funding through OGI’s Pre-commercialization Business Development Fund (PBDF), a unique investment fund which provides early-stage funding to genomics research and technology development, enabling commercialization. Read the interview to learn more about InDanio’s innovative technology.